OUR BOARD

Houman Ashrafian

Executive Chair

Houman Ashrafian
Executive Chair
Houman Ashrafian is Managing Partner at SV. He joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded five SV companies; Sitryx, Enara Bio, Zarodex, TrexBio and Alchemab. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee and as a Director of Karus Therapeutics.
 Previously, Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. Heart Metabolics successfully repositioned perhexiline, as a treatment for hypertrophic cardiomyopathy and heart failure. Perhexiline is now in advanced clinical trials and has orphan drug designation. He went on to become Vice President and head of the Clinical Science Group at UCB Pharma.

Kate Bingham

Board Member

Kate Bingham
Board Member
Kate Bingham is Managing Partner at SV and responsible for biotech investments and activities in the UK and EU. Her investments include small-molecule, biotherapeutic and gene therapy drug discovery and development projects as well as drug discovery platforms in a broad range of clinical areas. In her 29 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer. She played an active role in setting up the Dementia Discovery Fund (DDF), an SV managed fund, and currently serves on the DDF Investment Committee. Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals and at Monitor Company, a strategy consulting firm. Kate won the 2017 Lifetime Achievement Award, presented by BioIndustry Association UK. She also serves on the Board of the Francis Crick Institute and sits on the Advisory Committee of Oxford University Spin-out Equity Management (OSEM).

Kevin Lee

Board Member

Kevin Lee
Board Member
Kevin Lee is Chief Executive Officer of Bicycle Therapeutics. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, he lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.

Neil Weir

Board Member

Neil Weir
Board Member
Neil Weir is CEO of Sitryx, a biotech in the field of immunometabolism. Prior to Sitryx, Neil was Senior Vice-President, Discovery, at UCB S.A. overseeing an integrated portfolio of small molecule and antibody projects immunology and neurology. Neil and his teams transitioned 33 new chemical entities into development in immunology, oncology, bone and neurology including the marketed medicines Cimzia, Besponsa and Romosozumab. Neil was an inventor of Cimzia® and dual signalling domain chimeric receptors now known as second generation CAR-Ts. Neil served as chair of the board of Beryllium BioSciences in Boston and as a non-exec member of the boards of the RNA Medicines company (Boston) and Ondek (Perth WA). Neil chaired the UK ABPI innovation board from 2012 to 2018, has been involved in various MRC advisory board positions and was a member of the steering board for the German federal government’s Neuroallianz consortium.

Susan Hill

Chief Executive Officer

Susan Hill
Chief Executive Officer
Susan Hill is Chief Executive Officer of Mestag Therapeutics. Susan joined Mestag from clinical complement company Gyroscope Therapeutics, where she served as Chief Business Officer and helped to drive the company’s $62m Series B. Prior, she was founding Chief Executive Officer of Orbit Biomedical ($12m Series A) and Chief Business Officer of Freeline Therapeutics. Previously, Susan served in the Business & Corporate Development team at Alexion (ALXN), and during an 8-year tenure at Merck Serono (MRK) in a series of Corporate & Business Development and Portfolio Management roles. Susan began her career in strategy consulting/M&A, followed by a 3-year tenure leading biotech seed investments.  She has an MA and PhD from the University of Cambridge and is a previous Fellow of the Securities Institute.

Fiona MacLaughlin

Board Member

Fiona MacLaughlin
Board Member
Fiona is a Senior Director, Venture Investments, at Johnson & Johnson Development Corporation (JJDC). Prior to joining JJDC, Fiona served as a Director at Inkef Capital, where she led both pharma and MedTech investments and held Board seats in a number of portfolio companies. A qualified pharmacist, Fiona is passionate about helping early-stage companies establish a value-building trajectory by engaging and challenging management and creating optimal development plans. Fiona began her career in biotech focusing on the development of non-viral gene therapy and other novel delivery solutions. A fundamental interest in philanthropy led her to the Wellcome Trust and a focus on translational funding, including establishing a fund to support the development of affordable healthcare technologies in India. Fiona’s transition to venture investing began with a move to Advent Life Sciences, where she was involved in helping shape and build a number of early-stage companies including Arrakis Therapeutics.